Cyclo Therapeutics, Inc.
CYTHDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Cyclo Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
CYTH is no longer listed, so this page shows Q4 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 22
- +3 vs. Q3 2024
- Shares held
- 2.26M
- −15.7K (−0.7%) vs. Q3 2024
- Total value
- $1.33M
- −$463.5K (−25.8%) vs. Q3 2024
- New holders
- 4
- 3 more added
- Sold out
- 1
- 6 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.10M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.5K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $769.0K |
| Q2 2022 | 13 | $795.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EPIQ Capital Group, LLC | 689,447 | $406.8K | 0.11% | −49,979−6.8% | Reduced |
| Vanguard Group Inc | 598,694 | $353.2K | 0.00% | 00.0% | Unchanged |
| Founders Fund V Management, LLC | 480,708 | $283.6K | 16.84% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 152,332 | $89.9K | 0.00% | 00.0% | Unchanged |
| Founders Fund VI Management, LLC | 110,023 | $64.9K | 100.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 83,822 | $49.5K | 0.00% | +301+0.4% | Added |
| Two Sigma Securities, LLC | 42,541 | $25.1K | 0.00% | +42,541 | New |
| State Street Corp | 39,530 | $23.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 21,736 | $12.8K | 0.00% | +14+0.1% | Added |
| Wealth Enhancement Advisory Services, LLC | 18,285 | $10.8K | 0.00% | −5,115−21.9% | Reduced |
| UBS Group AG | 11,987 | $7.07K | 0.00% | −471−3.8% | Reduced |
| Tower Research Capital LLC (TRC) | 6,684 | $3.94K | 0.00% | +1,289+23.9% | Added |
| Wells Fargo & Company | 4,391 | $2.59K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,031 | $608 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 193 | $114 | 0.00% | −1−0.5% | Reduced |
| Bank of America Corp | 170 | $100 | 0.00% | −824−82.9% | Reduced |
| Steward Partners Investment Advisory, LLC | 90 | $53 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 67 | $39 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 30 | $18 | 0.00% | +30 | New |
| SBI Securities Co., Ltd. | 11 | $6 | 0.00% | +11 | New |
| BNP Paribas Arbitrage, SA | 1 | $1 | 0.00% | +1 | New |
| Royal Bank of Canada | 746 | $0 | 0.00% | −75−9.1% | Reduced |
| Princeton Global Asset Management LLC | 0 | $0 | 0.00% | −3,466−100.0% | Sold out |